OncotoX-AML / Omeros - LARVOL DELTA

Omeros Announces Successful Primate Study in OncotoX-AML Drug Program (Businesswire) - "Administration of only one course of OncotoX-AML treatment to immunocompetent primates demonstrated the desired pharmacologic response, specifically marked, selective, reversible, and dose-related reduction in myeloid progenitor cells - the cells that can mutate and lead to AML - by up to 99 percent. OncotoX-AML was well tolerated, without causing broader or lasting hematologic changes while preserving hematopoietic stem cells....'We look forward to advancing OncotoX-AML to the clinic, targeting a first-in-human trial for late 2027'."

First-in-human • New trial • Preclinical • Acute Myelogenous Leukemia